Ascentage Pharma Group International (Ticker: AAPG) is a China-based biopharmaceutical company focused on discovering, developing, and commercializing therapies for hematological malignancies and other diseases with unmet medical needs.

The company will uplist to the Nasdaq on January 24, 2025, offering 7.325 million American Depositary Shares (ADSs) at $20.34 per ADS, representing a total offering size of approximately $149.0 million. Each ADS represents four ordinary shares. Ascentage Pharma’s ordinary shares have been listed on the Hong Kong Stock Exchange (HKEx) since 2019 under the ticker “6855.” The company’s estimated market capitalization is $1.75 billion.

The offering is managed by J.P. Morgan and Citigroup. Proceeds from the offering will be used to advance clinical trials, pursue regulatory approvals, and support the company’s continued growth and development of therapies for hematological malignancies.